Single-cell RNA-sequencing identifies unique cell-specific gene expression profiles in high-grade cardiac allograft

Kaushik Amancherla1, Kelly H Schlendorf2, Nelson Chow2

  • 1Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

Insights

Single-cell analysis reveals distinct gene expression patterns in cardiac allograft vasculopathy (CAV), offering potential for new diagnostic biomarkers and targeted therapies to improve heart transplant outcomes.

Area of Science:

  • Immunology
  • Cardiology
  • Genomics

Background:

  • Cardiac allograft vasculopathy (CAV) is a primary cause of graft failure and mortality post-heart transplantation (HT).
  • Current diagnostic and therapeutic strategies for CAV are insufficient.

Purpose of the Study:

  • To investigate cell-specific gene expression profiles and T cell receptor repertoires in CAV using single-cell RNA-sequencing.
  • To identify novel biomarkers and therapeutic pathways for CAV pathogenesis.

Main Methods:

  • Single-cell RNA-sequencing was performed on peripheral blood mononuclear cells (PBMCs) from HT recipients with and without CAV.
  • Analyses included differential gene expression, cell composition changes, and T cell receptor repertoire analysis.

Main Results:

  • Significant increases in CD4+ T central memory cells and monocytes were observed in high-grade CAV.
  • 745 cell-specific differentially expressed genes were identified, enriched in inflammation and angiogenesis pathways.
  • 68 potential therapeutic targets were prioritized, including those with existing cardiovascular drugs.

Conclusions:

  • Single-cell transcriptomic analysis reveals unique, cell-specific gene expression patterns in CAV.
  • Peripheral gene expression biomarkers show potential for CAV diagnosis.
  • Targeting identified pathways may offer new therapeutic strategies for CAV.
Abstract